Stemline Therapeutics, Inc. (STML) and The Leukemia & Lymphoma Society Announce Collaboration to Accelerate the Development of SL-401 in Hematologic Cancers and Increase Awareness of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
10/29/2013 9:41:25 AM
NEW YORK, Oct. 29, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) and The Leukemia & Lymphoma Society® (LLS) today announced their collaboration to accelerate the development of SL-401 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematological disorder with both leukemic and lymphomatous characteristics. LLS has committed over $3 million to support this effort, as well as providing a comprehensive educational program to increase physician and patient awareness of BPDCN.
Help employers find you! Check out all the jobs and post your resume.
comments powered by